Stemline Therapeutics Inc (NASDAQ:STML)’s share price hit a new 52-week low during trading on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $12.60 and last traded at $13.25, with a volume of 19991 shares traded. The stock had previously closed at $14.58.
The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.06).
A number of equities analysts have issued reports on the company. BidaskClub cut Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, November 2nd. ValuEngine cut Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the stock a “buy” rating in a report on Friday, August 10th. Finally, Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 16th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $30.00.
The stock has a market cap of $462.77 million, a P/E ratio of -4.49 and a beta of 0.58.
Stemline Therapeutics Company Profile (NASDAQ:STML)
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
See Also: Risk Tolerance
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.